Status:
UNKNOWN
Metformin in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)
Lead Sponsor:
Kaplan Medical Center
Conditions:
Liver Diseases
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The purpose of this study is to examine the effect of metformin on biochemical and histological findings in NAFLD patients with insulin resistance syndrome.
Detailed Description
Study population: 30 patients will be included who meet all the following criteria: ALT \> 2 times normal range; liver histology revealing NASH (type 2-4), without cirrhosis; clinical characteristics...
Eligibility Criteria
Inclusion
- ALT \> 2 times normal range.
- Liver histology revealing non-alcoholic steatohepatitis \[NASH\] (type 2-4), without cirrhosis.
- Clinical characteristics of the metabolic syndrome as defined by the National Cholesterol Education Program (NCEP), but no overt diabetes.
- Negative work-up for other causes of liver diseases including alcohol intake \< 40 g/week.
Exclusion
- Diabetes mellitus.
- Alcohol intake \> 40 g per week.
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
August 1 2005
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00247117
Start Date
January 1 2004
End Date
August 1 2005
Last Update
October 9 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Endocrinology, Kaplan Medical Center
Rehovot, Israel, 76100